title: Acute and chronic effects of kisspeptin-54 administration on GH, prolactin and TSH secretion in healthy women.
abstract: BACKGROUND
  The peptide hormone kisspeptin is essential for human reproduction, acting on the hypothalamus to stimulate gonadotrophin-releasing hormone (GnRH) secretion. Kisspeptin is currently being evaluated as a novel therapeutic for women with infertility. However, some animal studies suggest that kisspeptin may also stimulate growth hormone (GH), prolactin and thyroid-stimulating hormone (TSH) secretion, with implications for its safety; no previous study has investigated whether kisspeptin stimulates these pituitary hormones in humans.
  
  
  OBJECTIVE
  To determine whether kisspeptin-54 modulates GH, prolactin and TSH secretion in healthy women.
  
  
  METHODS
  Prospective, single-blinded, placebo-controlled, one-way crossover study. Five healthy women received 7 days of twice-daily subcutaneous bolus vehicle (month 1) or 6·4 nmol/kg kisspeptin-54 (month 2).
  
  
  METHODS
  Serum samples were analysed post hoc for GH, prolactin and TSH.
  
  
  RESULTS
  Mean serum GH, PRL and TSH did not change during the first 4 h following kisspeptin-54 injection when compared with vehicle. The mean frequency or amplitude of GH pulses (which influence GH function) did not change acutely following kisspeptin-54 injection when compared with vehicle. No chronic changes in serum GH, PRL or TSH were observed over the 7-day period of twice-daily kisspeptin-54 injections when compared with vehicle.
  
  
  CONCLUSIONS
  While we cannot exclude any effect of kisspeptin-54 on GH, prolactin or TSH secretion, we observed no significant changes in these hormones at a dose of kisspeptin-54 administration known to stimulate gonadotrophin secretion in a small study of healthy women. These data have important implications for the potential of kisspeptin to treat patients with infertility.
authors.affiliation: Section of Investigative Medicine, Imperial College London, Hammersmith Hospital, London, UK.
authors.forename: Channa N
authors.initials: CN
authors.lastname: Jayasena
authors.forename: Alexander N
authors.initials: AN
authors.lastname: Comninos
authors.forename: Shakunthala
authors.initials: S
authors.lastname: Narayanaswamy
authors.forename: Sanjana
authors.initials: S
authors.lastname: Bhalla
authors.forename: Ali
authors.initials: A
authors.lastname: Abbara
authors.forename: Zainab
authors.initials: Z
authors.lastname: Ganiyu-Dada
authors.forename: Mark
authors.initials: M
authors.lastname: Busbridge
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Ghatei
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Bloom
authors.forename: Waljit S
authors.initials: WS
authors.lastname: Dhillo
mesh_terms: D000328:Adult; D018592:Cross-Over Studies; D005260:Female; D019382:Human Growth Hormone / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D059648:Kisspeptins / Q000494:pharmacology*; D011388:Prolactin / Q000187:drug effects* / Q000378:metabolism; D016037:Single-Blind Method; D013972:Thyrotropin / Q000187:drug effects* / Q000378:metabolism; D055815:Young Adult
chemical_list: C106628:KISS1 protein, human; D059648:Kisspeptins; D019382:Human Growth Hormone; D011388:Prolactin; D013972:Thyrotropin